Experience of Uncommon EGFR Mutation in Lung Scheme Quality Program: Discussing Risks and Opportunities for the Improvement of Laboratory Response

Abstract

Background The quality programs can be considered to be a valuable tool for global and individual growth. Each result, obtained by a single laboratory, contributes to define the standardization of the response. In the case of the uncommon epidermal growth factor receptor (EGFR) mutations, the molecular result is sometimes difficult to interpret in terms of biological significance and therapy choosing. The standardization effort in the diagnostic lung setting also consists of active quality program participation.
Materials and Methods The quality control analysis, which is defined as a clinical case, was performed by the extraction of DNA from FFPE sections and by RT-PCR on the EGFR (exons 19, 20, 21), BRAF, and KRAS genes. The laboratory performed a validation sequencing of EGFR exon 20 with the help of the Sanger method.
Results The laboratory reported positivity for EGFR exon 20 insertions and negative results for BRAF and KRAS. The quality test finished with the redaction of a report containing the recommendation to consider the efficacy of therapy with tyrosine kinase inhibitors (TKI). This specific interpretation has determined poor performance judgment by the quality provider, which explained why most of these mutations are TKI-resistant.
Conclusions This experience provides an opportunity to reflect on the critical aspects of this diagnostic setting. The detection of some uncommon EGFR mutations should entail the mutation characterization, especially for the rare exon 20 insertions, of which are not classifiable as “resistant.” Moreover, this experience allows reflecting on the quality program design, mandatory actions for the laboratory, and routine activity in the oncologic multidisciplinary team.

Keywords

uncommon EGFR mutations / TKIs / quality programs

References

[1] Wu JY,Wu SG, Yang CH, et al.Lung cancer with epidermal growth factor receptor exon 20mutations is associatedwith poor gefitinib treatment response. Clin Cancer Res 2008;14(15):4877-4882

[2] Greulich H, Chen TH, Feng W, et al.Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2005; 2(11):e313

[3] Oxnard GR, Lo PC, Nishino M, et al.Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol 2013;8(02):179-184

[4] Zhang T, Wan B, Zhao Y, et al.Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Transl Lung Cancer Res 2019;8(03):302-316

[5] Hirano T, Yasuda H, Tani T, et al.In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Oncotarget 2015;6(36):38789-38803

[6] Jia Y, Juarez J, Li J, et al.egf816 exerts anticancer effects in nonsmall cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor. Cancer Res 2016;76(06):1591-1602

[7] Yasuda H, Park E, Yun CH, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med 2013;5(216):216ra177

[8] Voon PJ, Tsui DW, Rosenfeld N, Chin TM.EGFR exon 20 insertion A763-Y764insFQEA and response to erlotinib-Letter. Mol Cancer Ther 2013;12(11):2614-2615

[9] Woo HS, Ahn HK, Lee HY, et al.Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors. Invest New Drugs 2014;32(06):1311-1315

[10] Yang JC, Sequist LV, Geater SL, et al.Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommonEGFRmutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 2015;16(07):830-838

[11] Robichaux JP, Elamin YY, Tan Z, et al.Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 2018;24(05):638-646

[12] Riely GJ, Neal JW, Camidge DR, et al.Activity and safety of mobocertinib (TAK-788) in previously treated non-small cell lung cancer with EGFR Exon 20 insertion mutations froma phase 1/2 trial. Cancer Discov 2021;11(07):1688-1699

[13] Yun J, Lee SH, Kim SY, et al.Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR Exon 20 insertion-driven NSCLC. Cancer Discov 2020;10(08):1194-1209

[14] Yan X, Lin Z, Lifang Z, Yingchun W, Mei W, Zhenfan Y. DZD9008, an oral, wild type selective EGFR inhibitor for the treatment of nonsmall- cell lung cancer with Exon20 insertion and other activating mutations. Cancer Res 2019. Doi: 10.1158/1538-7445.AM2019- 3081

[15] Udagawa H, Hasako S, Ohashi A, et al.TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase inhibitor with a broad spectrum of preclinical activity against clinically relevant EGFR mutations. Mol Cancer Res 2019;17(11): 2233-2243

[16] Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol 2013;66(02):79-89

[17] Beau-Faller M, Prim N, Ruppert AM, et al. When should we order a next generation sequencing test in a patient with cancer? EClinicalMedicine 2020;25:100487

[18] Patton S, Normanno N, Blackhall F, et al.Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing. Br J Cancer 2014;111(02):413-420

[19] Beau-Faller M, Prim N, Ruppert AM, et al.Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol 2014;25(01):126-131

RIGHTS & PERMISSIONS

2021 Global Medical Genetics